Genetic Testing Market By Type (Carrier Testing, Diagnostic Testing, Newborn Screening, Predictive and Presymptomatic Testing, Prenatal Testing, and Other Types), By Disease (Alzheimer’s Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s Disease, Rare Diseases, and Other Diseases), By Technology (Cytogenetic Testing, Biochemical Testing, and Molecular Testing), and By Region, Trends, Analysis and Forecast till 2034

Genetic Testing Market accounted for USD 11.0 Billion in 2024 and is estimated to be USD 24.2 Billion by 2034 and is anticipated to register a CAGR of 9.0%.

Genetic testing is the study of the gene present in cells and tissues. This study is further applied in the field of medicine and biology to better understand genetic disorders such as cancer, cystic fibrosis, sickle cell anaemia, Down syndrome, and others. Genetic testing technology (laboratory developed test (LDT) and direct-to-customer) has undergone significant improvements after the technology came into existence. With scientific advancements in genomics, genetic testing has become a common procedure in clinics. In addition, the adoption rate for direct-to consumer is high and is expected to increase over the forecast period. Regulatory authorities (such as Food and Drug Administration (FDA) and European Medicines Agency (EMA)) and insurance providers (such as Centers for Medicare and Medicaid Services (CMS), and others) have not been able to improve their guidelines, with changing technology and environment. The current legislation has given enforcement agencies the discretionary power for premarket review and quality system requirements, for both traditional and rare disease LDTs. Although this discretionary power can be helpful in increasing the efficiency and efficacy, it delays the overall process, which is not good for such a rapidly evolving, technology-oriented market. As a result, there has been a struggle between the market players and regulatory authorities. For instance, the 23andme Company markets personal genetic tests directly to customers and has been operating in a similar way, since 2006. In 2013, owing to the company’s failure to provide information to back its marketing claims, the FDA banned its personal genetic test kits. The continuous tussle between market players and regulatory authorities, with respect to evolving technology, presents a challenging environment for the new and established players in the market.

Rise in incidence of genetic disorders

The rise in the incidence of genetic disorders & cancer and growth in awareness & acceptance of personalized medicines is the major factor driving the growth of the genetic testing market. Also, increasing the application of genetic testing and advancements in genetic testing techniques in oncology are projected to boost the target market growth over the forecast period. According to the data published by NCBI, in August 2017, there were about 75,000 genetic tests available in the market, these include an approximate of 10,000 unique tests. Also, there has been an addition of more than 14,000 tests in the market since March 2014.

However, stringent regulatory requirements for product approvals and standardization concerns regarding genetic testing-based diagnostics are expected to hamper the genetic testing market growth over the forecast period. Nevertheless, untapped emerging markets in developing countries are estimated to provide lucrative growth opportunities for global market players. Therefore, these factors are anticipated to propel the genetic testing market share.

The genetic testing market is segmented based on type, disease, technology, and region.

Based on type, the genetic testing market is segmented into carrier testing, diagnostic testing, newborn screening, predictive and presymptomatic testing, prenatal testing, and other types. Based on disease, the target market is classified into Alzheimer’s disease, cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington’s disease, Rare Diseases, and Other Diseases. Based on technology, the target market is classified into cytogenetic testing, biochemical testing, and molecular testing.

Region:

On the region, the genetic testing market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2017, North America was the leading revenue contributor to the genetic testing market and is projected to dominate the market over the forecast period. This is mainly credited due to the occurrence of the majority of key players in this region. Moreover, Asia-Pacific is anticipated to grow at the highest CAGR over the forecast period, owing to a surge in healthcare expenditure, increase in affordability, and growth in awareness toward early screening of genetic disorders.

Genetic Testing Market Report Scope:

Genetic Testing Market, By Type:

• Carrier Testing
• Diagnostic Testing
• Newborn Screening
• Predictive and Presymptomatic Testing
• Prenatal Testing
• Other Types

Genetic Testing Market, By Disease:

• Alzheimer’s disease
• Cancer
• Cystic Fibrosis
• Sickle Cell Anemia
• Duchenne Muscular Dystrophy
• Thalassemia
• Huntington ’s disease
• Rare Diseases
• Other Diseases

Genetic Testing Market, By Technology:

• Cytogenetic Testing
• Biochemical Testing
• Molecular Testing

Genetic Testing Market, By Region:

• North America
  • Middle East & Africa
    • Middle East & Africa Genetic Testing Market, By Type
    • Middle East & Africa Genetic Testing Market, By Disease
    • Middle East & Africa Genetic Testing Market, By Technology
    • Middle East & Africa Genetic Testing Market, By Country
      • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • Latin America Genetic Testing Market, By Type
    • Latin America Genetic Testing Market, By Disease
    • Latin America Genetic Testing Market, By Technology
    • Latin America Genetic Testing Market, By Country
      • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • Asia Pacific Genetic Testing Market, By Type
    • Asia Pacific Genetic Testing Market, By Disease
    • Asia Pacific Genetic Testing Market, By Technology
    • Asia Pacific Genetic Testing Market, By Country
      • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • Europe Genetic Testing Market, By Type
    • Europe Genetic Testing Market, By Disease
    • Europe Genetic Testing Market, By Technology
    • Europe Genetic Testing Market, By Country
      • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • North America Genetic Testing Market, By Type
  • North America Genetic Testing Market, By Disease
  • North America Genetic Testing Market, By Technology
  • North America Genetic Testing Market, By Country
    • U.S.
    • Canada

The key players operating the genetic testing market 23andMe, Abbott Laboratories Inc., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd., Danaher Corporation (Cepheid), Genesis Healthcare, Illumina Inc., Luminex Corporation, Eurofins Scientific SE (Eurofins), and Myriad Genetics Inc. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the types to gain a competitive edge in the target market. For instance, in March 2018, Thermo Fisher Scientific acquired IntegenX, a provider of leading rapid DNA technology for human identification.

• 23andMe
• Abbott Laboratories Inc.
• Bio-Rad Laboratories
• F. Hoffmann-La Roche Ltd.
• Danaher Corporation (Cepheid)
• Genesis Healthcare
• Illumina Inc.
• Luminex Corporation
• Eurofins Scientific SE (Eurofins)
• Myriad Genetics Inc.